Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MacroGenics, Inc. (MGNX : NSDQ)

• Company Description    MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. Number of Employees: 341

• Price / Volume Information    Yesterday's Closing Price: $1.37 Daily Weekly Monthly 20 Day Moving Average: 829,324 shares Shares Outstanding: 63.21 (millions) Market Capitalization: $86.59 (millions) Beta: 1.55 52 Week High: $4.54 52 Week Low: $0.99 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.93% -21.06% 12 Week -13.29% -16.89% Year To Date -57.85% -63.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9704 MEDICAL CENTER DRIVE - Rockville,MD 20850 USA ph: 301-251-5172 fax: 301-251-5321 info@macrogenics.com http://www.macrogenics.com

• General Corporate Information    Officers Scott Koenig - Chief Executive Officer;President and Director James Karrels - Senior Vice President;Chief Financial Officer and Beth Smith - Vice President; Controller and Treasurer Karen Ferrante - Director William Heiden - Director Peer Information MacroGenics, Inc. (BJCT) MacroGenics, Inc. (CADMQ) MacroGenics, Inc. (APNO) MacroGenics, Inc. (UPDC) MacroGenics, Inc. (IMTIQ) MacroGenics, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 556099109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 63.21 Most Recent Split Date: (:1) Beta: 1.55 Market Capitalization: $86.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.46 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.24 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.85 Price/Cash Flow: - Price / Sales: 0.52 EPS Growth vs. Year Ago Period: 35.96% vs. Previous Quarter: 12.31% Sales Growth vs. Year Ago Period: 105.99% vs. Previous Quarter: 68.59% ROE 09/30/25 - - 06/30/25 - -40.24 03/31/25 - -59.84 ROA 09/30/25 - - 06/30/25 - -14.62 03/31/25 - -23.45 Current Ratio 09/30/25 - - 06/30/25 - 5.26 03/31/25 - 3.28 Quick Ratio 09/30/25 - - 06/30/25 - 5.02 03/31/25 - 3.11 Operating Margin 09/30/25 - - 06/30/25 - -21.99 03/31/25 - -36.23 Net Margin 09/30/25 - - 06/30/25 - -21.99 03/31/25 - -36.23 Pre-Tax Margin 09/30/25 - - 06/30/25 - -21.36 03/31/25 - -35.62 Book Value 09/30/25 - - 06/30/25 - 0.74 03/31/25 - 1.25 Inventory Turnover 09/30/25 - - 06/30/25 - 3.95 03/31/25 - 4.52 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©